Right now, the HALT Study is underway to provide the substantial evidence of effectiveness necessary for the full FDA approval of Felycin-CA1 (referred to as TRIV202 in HALT) for the management of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback